Lipocalin 2 deactivates macrophages and worsens pneumococcal pneumonia outcomes

Insights

Lipocalin 2 (LCN2) deactivates macrophages, suppressing inflammation and impairing bacterial clearance. Elevated LCN2 in pneumonia indicates a worse outcome, highlighting its role in infection severity.

Area of Science:

  • Immunology
  • Microbiology
  • Respiratory Medicine

Background:

  • Macrophages are crucial for pathogen response and inflammation.
  • Deactivated macrophages resolve inflammation but lack specific markers.
  • Understanding macrophage subsets is key to infection outcomes.

Purpose of the Study:

  • Identify markers for deactivated macrophages.
  • Investigate the role of lipocalin 2 (LCN2) in macrophage deactivation.
  • Determine LCN2's impact on bacterial pneumonia and survival.

Main Methods:

  • Identified LCN2 as a marker and deactivator of macrophages.
  • Assessed LCN2's effect on inflammatory response and bacterial clearance in mice.
  • Analyzed LCN2 and IL-10 induction via STAT3 signaling.
  • Correlated pulmonary LCN2 levels with human pneumonia outcomes.

Main Results:

  • LCN2 attenuated early inflammation and impaired bacterial clearance in pneumococcal pneumonia models.
  • LCN2 induced interleukin-10 (IL-10) production by macrophages, promoting a STAT3-dependent polarization.
  • Human bacterial pneumonia showed elevated pulmonary LCN2 levels.
  • High LCN2 levels correlated with detrimental outcomes in Gram-positive bacterial pneumonia.

Conclusions:

  • Macrophage deactivation is critical for pneumococcal infection outcomes.
  • LCN2 acts as a key deactivator of macrophages in the respiratory tract.
  • LCN2 and IL-10 are significant determinants of macrophage function during respiratory infections.